- 
HIMS is quite overvalued. There's no moat to a business model.
- They got a good branding that's all. There are 10-15 other startups selling the same things under different umbrella.
- They even stole
NVO flagship weight loss drugs. These cheap alternatives will risk lives of people and will open plethora of lawsuits.
- Growth is slowing down to low 20s which calls for correction in the multiple.
- Anyone paying more than 20x will likely suffer from massive losses within an year timeframe.
- Fundamentally,
Year | 2025 | 2026 | 2027 | 2028
EPS | 0.57 | 0.79 | 1.05 | 1.40
EPS% | 5.76% | 38.31% | 32.59% | 33.25%
Giving benefit of doubt and being generous, 30x multiple as a base case. Fair stock value:
Year | 2025 | 2026 | 2027 | 2028
Price | $17 | $23 | $31 | $42
- We should visit the $23-26 range somewhere in 2026
HIMS is quite overvalued. There's no moat to a business model. - They got a good branding that's all. There are 10-15 other startups selling the same things under different umbrella.
- They even stole
NVO flagship weight loss drugs. These cheap alternatives will risk lives of people and will open plethora of lawsuits. - Growth is slowing down to low 20s which calls for correction in the multiple.
- Anyone paying more than 20x will likely suffer from massive losses within an year timeframe.
- Fundamentally,
Year | 2025 | 2026 | 2027 | 2028
EPS | 0.57 | 0.79 | 1.05 | 1.40
EPS% | 5.76% | 38.31% | 32.59% | 33.25%
Giving benefit of doubt and being generous, 30x multiple as a base case. Fair stock value:
Year | 2025 | 2026 | 2027 | 2028
Price | $17 | $23 | $31 | $42
- We should visit the $23-26 range somewhere in 2026
Note
- Given the stock is currently trading at $52.54 as of October 4, 2025. Risk/Reward is to the downside.-
HIMS could crash around 50% within one year
Related publications
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.
Related publications
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.